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Cancer, inflammation and immune surveillance recruit lymphocytes as common key cellular players. The aim of the study was 
to assess a utility of the absolute and relative lymphocyte counts (ALC and RLC) in peripheral blood of patients with urological 
cancer as sensitive tool in pretreatment assessment of patient, which correlates with postoperative outcome of the disease, and 
outlines the overall reactivity of the patient. Materials and Methods: We retrospectively studied correlation between lymphocyte 
count in peripheral blood of the patients with urological cancer (n = 789) and number of clinical parameters: cancer localization, 
stage of the disease, treatment outcome, complications. Mann — Whitney two-tailed test and logistic regression models were used. 
Results: Lymphocyte counts (both absolute and relative) correlate with the cancer stage, and status of the disease, allowing dif-
ferentiate patients with urological cancer, from healthy individuals, and from the cancer patients after radical surgery. In patients 
with kidney and bladder cancer, lymphocyte count allowed differentiate the stages of the disease. Lower rate of the reactivity of the 
patient to the cancer treatment is accurately predicted by the ALC and RLC: those in highest quartile for lymphocytes count have 
shorter postoperative recovery. Patients in lowest quartile demonstrated worst postoperative performance, including cases of early 
postoperative mortality due to weak somatic status. Conclusion: The study presents evidence that pretreatment lymphocyte count 
in the peripheral blood of patients with urological cancer is a sensitive marker of cancer stage, and the reactivity of the patient 
to the cancer treatment, which can be used in the pretreatment assessment of the patient.
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Cancer progression, chronic inflammation and 
strength of immune response are the phenomena 
tightly connected and interrelated in a diseased per-
son [1, 2]. Each of entities either predisposes, main-
tains, or facilitates the progression of each of those 
conditions, in particular, chronic inflammation serves 
as basis for cancer initiation, cancer progression 
causes suppression of the immune system, includ-
ing induction of apoptosis of T-lymphocytes [3–5], 
immunosuppression facilitates carcinogenesis [3]. 
The cellular (white blood cells) and molecular (cy-
tokines, chemokines) mediators are common for all 
those three processes, which make them universal 
indicators of the state of the disease and reactivity 
of the patient.
The assessment of the patients’ reactivity 
is an important step in managing urological ma-
lignancy, as it relates to the ability to recover after 
the planned treatment, have less postoperative 
complications and shorter stay after surgery [6]. 
It is well known that any modality in cancer treat-
ment bears the immunosuppressive potential. 
Thus, knowledge of the basic reactivity of the pa-
tient and scope of its ability to cope with the stress 
caused by cancer itself and cancer treatment can 
be additional study in pretreatment clinical evalu-
ation of the patient.
The aim of the study was to validate the absolute 
and relative count of lymphocytes in peripheral blood 
in patients prior to surgical treatment as sensitive and 
informative tool in pretreatment assessment of the 
patient, which correlates with postoperative outcome 
of the disease, and outlines the overall reactivity of the 
patient.
MATERIALS AND METHODS
We retrospectively studied the medical records 
of 789 patients who during 2014–2016 received sur-
gical treatment at the Department of Urology for uro-
logical cancer. The study objects included: 1) blood 
analysis before treatment, in particular, absolute 
lymphocyte count (ALC) and relative lymphocyte count 
(RLC) — percentage of lymphocytes in relation to all 
white blood cells in peripheral blood; 2) final diagnosis 
at the discharge; 3) stage of cancer; 4) treatment out-
come, 5) length of postoperative stay. Blood analyses 
were performed at the same automatic blood analyzer, 
the results entered into a database, and analyzed with 
MS Office Excel software.
The study protocol was reviewed and endorsed 
by the Ethics Committee.
All patients were distributed into three groups: 
group I — 722 patients with primary urological cancer 
scheduled to receive cancer treatment; group II — 
67 cancer patients who had received radical cancer 
treatment more than 3 months ago and at the moment 
of this study had no signs of recurrence or progres-
sion, and were considered “recovered”; group III — 
62 healthy individuals without cancer, who came to the 
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clinic for a regular check-up. The results of their blood 
analysis were considered as control group for the 
purpose of this study.
We used the data from these three groups to con-
duct mathematical analysis of correlation between 
the status of the disease (primary urological cancer, 
recovered cancer patients, and cancer-free patients) 
and lymphocyte counts in peripheral blood. We applied 
Mann — Whitney two-tailed test with a significance 
level of 0.05 to assess if difference exists between 
study groups based on the investigated countable 
parameters (ALC and RLC).
At the second part of our study we focused only 
on the patients from the group I — those with most 
frequent urological cancer (urinary bladder, prostate, 
kidney) — to test if ALC and RLC may differentiate the 
stage of the cancer. Table 1 presents the distribution 
of patients among the cancer types. Table 2 presents 
the distribution of patients with most frequent cancer 
per stage based on TNM classification.
Table 1. Localization of urological tumors in the study group
Tumors Number of patients
Urinary bladder cancer 269
Kidney cancer 140
Prostate cancer 138
Testicular cancer 87
Penile cancer 21
Renal pelvis cancer 20
Adrenal gland cancer 7
Sarcoma 6
Ureteral cancer 4
Multiple tumors of urological organs 30
Total 722
Table 2. Distribution of patients by tumor localization and TNM stage
Localization, stage Number of patients
Urinary bladder
Stage I 170
Stage II 43
Stage III 32
Stage IV 24
Subtotal 269
Kidney
Stage I 59
Stage II 35
Stage III 26
Stage IV 20
Subtotal 140
Prostate
Stage I 1
Stage II 55
Stage III 43
Stage IV 39
Subtotal 138
TOTAL 547
We applied Mann — Whitney two-tailed test to each 
pair of stages (I and II, I and III, etc.) in every cancer 
type subgroup to assess if difference exists between 
study population of particular stage in each cancer 
type subgroup based on the ALC and RLC.
To assess the correlation between preoperative lym-
phocyte count and length of postoperative stay we used 
the data on 35 patients with kidney cancer of stage II who 
underwent radical nephrectomy. The model of binary 
logistic regression was used for this purpose.
RESULTS
Mean ALC and RLC in study groups (I, II, III) are pre-
sented in Tables 3, 4, and points at evident differences 
in these indexes between study groups. In particular, the 
lowest ALC and RLC values were observed in the group 
of cancer patients, and the highest — in cancer patients 
after radical treatment. This fact highlights the suppres-
sive effect of the tumor on lymphopoetic branch, and 
stimulatory effect on myeloid lineage of hemopoesis, 
which maintains the inflammatory state. Surgical removal 
of the tumor, even in the setting of the stage IV patients 
with cytoreductive purpose, leads to correction of the 
lymphocytes count in the blood analysis, which even 
exceeds such of the healthy control patients (group III). 
Based on these data we can acknowledge that surgical 
removal of the tumorous tissue reduces the immunosup-
pressive effect of the cancer, and on other hand, allevi-
ates the inflammatory effect of the tumor on the body.
Table 3. Mean ALC in peripheral blood in groups I–III, •103/ml
Group Number of patients
ALC Standard 
deviationMinimum Maximum Mean
I Primary can-
cer before 
treatment
722 0.3 4.1 1.720 0.548
II Cancer af-
ter definitive 
treatment
67 1.0 4.5 2.034 0.755
III Healthy con-
trols
62 1.0 3.6 1.974 0.582
Table 4. Mean RLC in peripheral blood of total white blood cell count in pe-
ripheral blood in groups I–III, %
Group Number of patients
RLC Standard 
deviationMinimum Maximum Mean
I Primary can-
cer before 
treatment
722 5.8 59.7 27.890 8.647
II Cancer af-
ter definitive 
treatment
67 16.7 60.0 32.888 8.874
III Control 62 13.6 48.8 32.294 7.504
To evaluate if patients’ study groups (I, II, and III) 
differ by mean absolute and relative level of lympho-
cytes in peripheral blood, we ran Mann — Whitney 
two-tailed test for ALC and RLC for each pair of com-
parison. The results are presented in Tables 5, 6.
Table 5. Results of Mann — Whitney two-tailed test for mean ALC in periphe-
ral blood in paired study groups
Criteria Pairs of patients’ groups for comparisonI–II I–III II–III
U 10,893.500 9280.000 724.000
Expected value 14,340.000 12,547.500 700.000
Variance (U) 1,804,682.55 1,568,879.1 8818.613
p-value (two-tailed) 0.010 0.009 0.802
Alpha 0.05 0.05 0.05
Table 6. Results of Mann — Whitney two-tailed test for RLC in peripheral 
blood in paired study groups
Criteria Pairs of patients’ groups for comparisonI–II I–III II–III
U 9777.000 8518.000 727.000
Expected value 14,340.000 12,547.500 700.000
Variance (U) 1,811,568.207 1,574,665.593 8864.901
p-value (two-tailed) 0.001 0.001 0.778
Alpha 0.05 0.05 0.05
Table 5 data indicate that there is statistically sig-
nificant difference in mean ALC count in peripheral 
blood between cancer patients and healthy controls 
(1.72 • 103/ml vs 1.97 • 103/ml, р = 0.009), and can-
cer patients and those who received radical cancer 
treatment (1.72 • 103/ml vs 2.03 • 103/ml, р = 0.01). 
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Cancer patients after radical treatment do not sta-
tistically differ in their ALC from the healthy controls 
(2.03 • 103/ml vs 1.97 • 103/ml, р = 0.8).
The data from Table 6 demonstrate statistically 
significant difference in RLC between cancer patients 
and healthy controls (27.9% vs 32.3%, р = 0.001), and 
between cancer patients and cancer patients after 
radical treatment (27.9% vs 32.9%, р = 0.001). As with 
ALC, the RLC in cancer patients after radical treatment 
does not differ from such in healthy controls (32.9% 
vs 32.3%, р = 0.78).
In order to answer the question if ALC and RLC 
can differentiate clinical stages (I, II, III or IV) in each 
type of cancer (urinary bladder, prostate and kidney) 
we determined mean for each parameter, and then 
performed Mann — Whitney two-tailed test for each 
pair of clinical stages. The results are presented 
in Table 7.
Table 7. ALC and RLC in peripheral blood in most frequent urological can-
cer types per TMN stage
Can-
cer and 
stage
Pa-
tients, 
n
Minimum 
ALC, 
• 103/ml
Maxi-
mum 
ALC, 
• 103/ml
Mean 
ALC, 
• 103/ml
Mini-
mum 
RLC
Max-
imum 
RLC
Mean 
RLC, %
Urinary bladder cancer
Stage I 170 0.300 3.900 1.777 7.500 53.000 29.529
Stage II 43 0.500 2.600 1.702 6.900 45.600 25.391
Stage III 32 0.700 3.500 1.816 11.400 39.600 25.803
Stage IV 24 0.500 3.100 1.596 8.700 43.600 23.271
Subtotal 269
Kidney cancer
Stage I 59 0.800 2.900 1.861 16.200 59.700 31.880
Stage II 35 0.900 2.600 1.654 15.400 45.000 27.786
Stage III 26 0.900 3.300 1.762 14.300 43.600 27.986
Stage IV 20 0.400 2.900 1.555 7.400 44.400 22.690
Subtotal 140
Prostate cancer
Stage I 1 − − 1.6 − − 26.7
Stage II 55 0.600 3.000 1.669 9.200 54.200 28.782
Stage III 43 0.700 4.100 1.799 14.100 53.400 29.395
Stage IV 39 0.700 3.400 1.544 12.700 42.500 26.372
Subtotal 138
TOTAL 547
The data from Table 7 indicate that in all urologi-
cal malignancies with progressing clinical stage one 
can observe the drop in absolute and relative number 
of lymphocytes in peripheral blood, favoring rise 
in neutrophil granulocytes. These data support the 
notion that progression of cancer occurs against pro-
gressing immunosuppression, reflected in declining 
level of lymphocytes.
The results of Mann — Whitney two-tailed test as-
sessing the significance of difference in ALC and RLC 
between stages I through IV in each type of cancer are 
presented in Tables 8–10 in binary fashion (“Yes” — 
there is difference, “No” — there is no difference).
Table 8. Difference in ALC and RLC between clinical stages of urinary 
bladder cancer cases
Cancer stage I II III IVALC RLC ALC RLC ALC RLC ALC RLC
I — — No Yes No Yes No Yes
II — — — — No No No No
III — — — — — — No No
IV — — — — — — — —
Note: RLC proved to be a valid criterion allowing differentiate patients with 
stage I bladder cancer from all others. To date, patients with bladder cancer 
of stage II–IV had RLC lower than in stage I.
Table 9. Difference in ALC and RLC between clinical stages of prostate 
cancer cases
Cancer 
stage
I II III IV
ALC RLC ALC RLC ALC RLC ALC RLC
I — — — — — — — —
II — — — — No No No No
III — — — — — — No No
IV — — — — — — — —
Table 10. Difference in ALC and RLC between clinical stages of kidney 
cancer cases
Cancer 
stage
I II III IV
ALC RLC ALC RLC ALC RLC ALC RLC
I — — Yes Yes No Yes Yes Yes
II — — — — No No No Yes
III — — — — — — No No
IV — — — — — — — —
Note: ALC and RLC in patients.
From the data presented in Table 8, we can con-
clude that for patients with bladder cancer the mean 
ALC may not differentiate stages of the cancer. Con-
trary, there is statistically significant difference for 
RLC between stage I and others stages. This means 
that the patients with bladder cancer of stage I have 
the highest RLC. Starting with stage II and up the RLC 
difference loses significance.
Table 9 represents the data on prostate cancer 
cases. Neither ALC nor RLC in peripheral blood of pa-
tients with prostate cancer play a role of valid diffe-
rentiation tool between stages. As there was only one 
patient with stage I prostate cancer, his data could not 
be included in calculation.
Table 10 demonstrates that in patients with kidney 
cancer ALC and RLC are of higher differentiating value, 
in particular, ALC allows differentiate stages I and II, 
and I and IV stage, while RLC allows differentiate 
stages I and all others (II, III and IV), and stages II and IV.
DISCUSSION
In routine clinical practice we use different quali-
tative and quantitative criteria and parameters which 
describe the somatic condition of the patient. We need 
to know how fit the patient is for the treatment. We also 
need to know how reactive the patient is, meaning how 
much resources patient has for recovering from the 
trauma caused by cancer treatment, how probable the 
complications are and what would be the anticipated 
length of postoperative stay.
It is commonly accepted and validated in the lit-
erature that ALC and neutrophil-to-lymphocyte (N/L) 
ratio are valid prognostic factors for survival in cancer 
patients [7–12]. The cut-off value for ALC is above 
1.3 • 103/ml, and for N/L ratio is below 2.4. The nor-
mal range for RLC in peripheral blood is above 19%. 
Falling ALC or rising N/L ratio (dropping RLC) are 
considered as predictors of poor prognosis, cancer 
progression, recurrence, or unfavorable treatment 
outcome. This statement reflects the notion that de-
velopment of cancer occurs against lymphocytopenia 
and neutrophilia. Neutrophils are the cells producing 
pro-angiogenic, anti-apoptotic and diverse growth 
factors, whereas lymphocytes are cells yielding innate 
and adoptive immunity against cancer cells.
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Another research has long time ago postulated and 
validated [13] that absolute and relative counts of lym-
phocytes in peripheral blood are reliable indicators of re-
activity of the organism and strength of immune system 
response required for combatting the disease. It was 
demonstrated, that “stress” (reaction of the physiologi-
cal systems to the extreme forces affecting the body) 
causes extreme lymphopenia below the cut-off thresh-
old of 1.3 • 103/ml for ALC, or 19% for RLC. Whereas fac-
tors less extreme and less stressful might lead to milder 
reaction of the immune system, which range from soft 
immunosuppression (falling ALC and RLC to above 
1.3 • 103/ml, or 19%) to even stimulation of immune 
reactivity (ALC and RLC rise to the upper limits of the 
normal range). The countable criterion, which reflects 
this phenomenon is relative count of lymphocytes in pe-
ripheral blood, thus making RLC a valuable diagnostic 
tool readily available in clinical blood test.
Study of urinary bladder carcinoma yielded valu-
able understanding of how cancer and immunity inter-
act. Bladder carcinomas have developed a mechanism 
to avoid immune-induced apoptosis [5]. Under normal 
conditions the Fas/Fas-ligand system mediates pro-
grammed cell death in cancerous tissues. Fas ligand 
is found primarily on T-lymphocytes and natural 
killer (NK) cells [14, 15]. Fas activation via binding 
of Fas ligand results in apoptosis of the cell bearing 
the receptor. Bladder carcinomas have developed 
a mechanism to avoid this immune response by remov-
ing Fas, effectively evading apoptosis [5]. Additionally, 
it has been shown that high-grade bladder cancers 
have developed resistance to Fas-ligand-induced 
apoptotic events downstream of Fas. It has been sug-
gested that the production and secretion of soluble Fas 
(sFas), produced by all bladder cancer cell lines may 
be able to block the action of T-lymphocytes and even 
induce apoptosis in immune cells [3, 5], reducing level 
of T cells in the peripheral blood.
Assessment of the immune status is not yet a rou-
tine practice in cancer clinic. The data presented above 
highlight that suppression of immune surveillance 
promotes the development and progression of cancer, 
which makes the immunological study a vital diagnos-
tic tool in the arsenal of oncologist.
The assessment of the immune status can be done 
at different levels of complexity: 1) basic blood analysis 
(which was used for this study), 2) analysis of cellular 
fractions (lymphocytes), functional cellular activity and 
humoral aspects of immune system (immunogram), 
3) HLA-phenotyping of lymphocytes to assess the 
defects in antigen-presentation machinery [16, 17]. 
All of those methods deliver particular diagnostic 
value to the assessment of immune system at rising 
cost and with rising level of accuracy. It is important 
to combine all available diagnostic tools. Still we need 
to acknowledge that the simplest and always readily 
available test — blood analysis — delivers accurate 
and valid data about the strength of immune surveil-
lance and reactivity of the patient, which may guide 
the clinical judgment. To illustrate this, out of our 
dataset, four patients with cancer of stage IV and 
lowest lymphocyte counts — ALC = 0.3–0.5 • 103/ml, 
and RLC% = 7.5–9.0 died in 3–4 weeks after surgery. 
At the same time, most of the patients with highest 
preoperative ALC and RLC had shortest postoperative 
stay compared to other patients after similar surgical 
procedures, but with worse results of ALC and RLC.
Based on this observation and on the results of our 
study, we can conclude that ALC and RLC in peripheral 
blood of patients with urological cancer are efficient 
and valid criteria, which allow to differentiate patients 
with urological cancer from those who were radically 
treated from cancer, and from those who are healthy. 
For the purpose of differentiating stages of the cancer, 
ALC and RLC are valid tools in some cases, such as: 
RLC differentiates stage I bladder cancer from the 
rest of stages; in kidney cancer ALC differentiates 
stage I and stage II, and I and IV, RLC — stage I from 
all others, and stage II from IV.
The reactivity of the patient’s immune system 
converts into outcome of the cancer treatment. The 
patients with highest preoperative ALC and RLC per-
formed best and had shortest postoperative stay, and 
those with lowest ALC and RLC demonstrated poorest 
results of postoperative stay and recovery, including 
four postoperative deaths during month after surgery 
for urological cancer.
CONCLUSION
ALR and RLC in peripheral blood are valid and sen-
sitive tests easily available in everyday clinical practice, 
correlating with the cancer stage and reflecting the 
progress, or status of the disease. The results of these 
tests allow to differentiate patients with urological 
cancer from healthy individuals, and from the cancer 
patients after radical surgery. Lymphocyte counts 
(both absolute and relative) are higher in patients af-
ter radical cancer treatment than in healthy controls, 
which signify immune-stimulative effect of radical 
surgical excision of the tumor and reduction of its im-
munosuppressive effect. In patients with kidney and 
bladder cancer, lymphocyte count allows differentiate 
the stages of the disease. The reactivity of the patient 
to the cancer treatment is accurately predicted by the 
ALR and RLC: those in highest quartile for ALC and RLC 
(above 2 • 103/ml, and above 32%, respectively) have 
shorter postoperative recovery and no postoperative 
complications. Patients with lowest ALC and RLC 
(below 1.3 • 103/ml, and below 19%, respectively) 
demonstrated worst postoperative performance, 
including cases of early postoperative mortality due 
to weak somatic status.
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